Read our Recent Headlines

May 25 Biotech Update

The market continues higher and the sector with it. We seem to be moving away from the previous lows with broader participation with SMID and large caps. This market continues.

May 24 Biotech Update

I do not think anything dramatic happened when I was away. The sector seems to be holding the support which is most important. In addition, one could perhaps argue that.

May 19 Biotech Update

The sector did well the other day especially given the weakness in the broader markets. We have, however, seen this before and last time the sector grossly underperformed once the.

May 18 Biotech Update

The sector remains in a precarious position, which is nothing new. ISI had a call yesterday with its technician and the overwhelming view on most of the stocks was that.

Dave-Trading – May edition

*** David Sobek is a disciplined value investor.  Using models, research, and fundamental data, David devises a value for biotech stocks, buys when significantly undervalued, and sells when significantly overvalued.***.

May 16 Biotech Update

We got some decent news flow to start the week both positive and negative. Who knows how that will balance out in terms of the sector general performance but this.

May 13 Biotech Update

I feel like we have been here before with the sector flirting with a major breakdown triggering another leg lower. We have yet to get that break but we are.


Quick Facts














Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.

The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate. Subscribe to Chimera Research Group and proceed with confidence.

Get Started!